Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 473

1.

Fc-gamma receptor polymorphisms, cetuximab therapy, and overall survival in the CCTG CO.20 trial of metastatic colorectal cancer.

Shepshelovich D, Townsend AR, Espin-Garcia O, Latifovic L, O'Callaghan CJ, Jonker DJ, Tu D, Chen E, Morgen E, Price TJ, Shapiro J, Siu LL, Kubo M, Dobrovic A, Ratain MJ, Xu W, Mushiroda T, Liu G.

Cancer Med. 2018 Oct 14. doi: 10.1002/cam4.1819. [Epub ahead of print]

2.

A Pharmacogenetic Prediction Model of Progression-Free Survival in Breast Cancer using Genome-Wide Genotyping Data from CALGB 40502 (Alliance).

Rashkin SR, Chua KC, Ho C, Mulkey F, Jiang C, Mushiroda T, Kubo M, Friedman PN, Rugo HS, McLeod HL, Ratain MJ, Castillos F, Naughton M, Overmoyer B, Toppmeyer D, Witte JS, Owzar K, Kroetz DL.

Clin Pharmacol Ther. 2018 Sep 27. doi: 10.1002/cpt.1241. [Epub ahead of print]

PMID:
30260474
3.

Low-Dose Abiraterone With Food: Rebutting an Editorial.

Szmulewitz RZ, Karrison T, Stadler WM, Ratain MJ.

J Clin Oncol. 2018 Sep 6:JCO2018793018. doi: 10.1200/JCO.2018.79.3018. [Epub ahead of print] No abstract available.

PMID:
30188785
4.

Reply to I.F. Tannock, P. Isaacsson Velho et al, M. Tiako Meyo et al, and F.J.S.H. Woei-A-Jin et al.

Szmulewitz RZ, Stadler WM, Ratain MJ.

J Clin Oncol. 2018 Sep 6:JCO2018793190. doi: 10.1200/JCO.2018.79.3190. [Epub ahead of print] No abstract available.

PMID:
30188784
5.

Time Is Money: Optimizing the Scheduling of Nivolumab.

Ratain MJ, Goldstein DA.

J Clin Oncol. 2018 Aug 27:JCO1800045. doi: 10.1200/JCO.18.00045. [Epub ahead of print] No abstract available.

PMID:
30148658
6.

The vitamin D receptor gene as a determinant of survival in pancreatic cancer patients: Genomic analysis and experimental validation.

Innocenti F, Owzar K, Jiang C, Etheridge AS, Gordân R, Sibley AB, Mulkey F, Niedzwiecki D, Glubb D, Neel N, Talamonti MS, Bentrem DJ, Seiser E, Yeh JJ, Van Loon K, McLeod H, Ratain MJ, Kindler HL, Venook AP, Nakamura Y, Kubo M, Petersen GM, Bamlet WR, McWilliams RR.

PLoS One. 2018 Aug 14;13(8):e0202272. doi: 10.1371/journal.pone.0202272. eCollection 2018.

7.

Do Patients With Advanced Cancer Have the Ability to Make Informed Decisions for Participation in Phase I Clinical Trials?

Hlubocky FJ, Sachs GA, Larson ER, Nimeiri HS, Cella D, Wroblewski KE, Ratain MJ, Peppercorn JM, Daugherty CK.

J Clin Oncol. 2018 Aug 20;36(24):2483-2491. doi: 10.1200/JCO.2017.73.3592. Epub 2018 Jul 9.

8.

A pharmacodynamic study of sirolimus and metformin in patients with advanced solid tumors.

Sehdev A, Karrison T, Zha Y, Janisch L, Turcich M, Cohen EEW, Maitland M, Polite BN, Gajewski TF, Salgia R, Pinto N, Bissonnette MB, Fleming GF, Ratain MJ, Sharma MR.

Cancer Chemother Pharmacol. 2018 Aug;82(2):309-317. doi: 10.1007/s00280-018-3619-3. Epub 2018 Jun 9.

PMID:
29948021
9.

Identification of a Genomic Region between SLC29A1 and HSP90AB1 Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance).

Li M, Mulkey F, Jiang C, O'Neil BH, Schneider BP, Shen F, Friedman PN, Momozawa Y, Kubo M, Niedzwiecki D, Hochster HS, Lenz HJ, Atkins JN, Rugo HS, Halabi S, Kelly WK, McLeod HL, Innocenti F, Ratain MJ, Venook AP, Owzar K, Kroetz DL.

Clin Cancer Res. 2018 Oct 1;24(19):4734-4744. doi: 10.1158/1078-0432.CCR-17-1523. Epub 2018 Jun 5.

PMID:
29871907
10.

Analyzing the clinical actionability of germline pharmacogenomic findings in oncology.

Wellmann R, Borden BA, Danahey K, Nanda R, Polite BN, Stadler WM, Ratain MJ, O'Donnell PH.

Cancer. 2018 Jul 15;124(14):3052-3065. doi: 10.1002/cncr.31382. Epub 2018 May 9.

PMID:
29742281
11.

Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer.

Szmulewitz RZ, Peer CJ, Ibraheem A, Martinez E, Kozloff MF, Carthon B, Harvey RD, Fishkin P, Yong WP, Chiong E, Nabhan C, Karrison T, Figg WD, Stadler WM, Ratain MJ.

J Clin Oncol. 2018 May 10;36(14):1389-1395. doi: 10.1200/JCO.2017.76.4381. Epub 2018 Mar 28.

PMID:
29590007
12.

Clinical pharmacodynamic/exposure characterisation of the multikinase inhibitor ilorasertib (ABT-348) in a phase 1 dose-escalation trial.

Maitland ML, Piha-Paul S, Falchook G, Kurzrock R, Nguyen L, Janisch L, Karovic S, McKee M, Hoening E, Wong S, Munasinghe W, Palma J, Donawho C, Lian GK, Ansell P, Ratain MJ, Hong D.

Br J Cancer. 2018 Apr;118(8):1042-1050. doi: 10.1038/s41416-018-0020-2. Epub 2018 Mar 19.

13.

Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors.

Luke JJ, Lemons JM, Karrison TG, Pitroda SP, Melotek JM, Zha Y, Al-Hallaq HA, Arina A, Khodarev NN, Janisch L, Chang P, Patel JD, Fleming GF, Moroney J, Sharma MR, White JR, Ratain MJ, Gajewski TF, Weichselbaum RR, Chmura SJ.

J Clin Oncol. 2018 Jun 1;36(16):1611-1618. doi: 10.1200/JCO.2017.76.2229. Epub 2018 Feb 13.

PMID:
29437535
14.

Genomic Heterogeneity Within Individual Prostate Cancer Foci Impacts Predictive Biomarkers of Targeted Therapy.

VanderWeele DJ, Finney R, Katayama K, Gillard M, Paner G, Imoto S, Yamaguchi R, Wheeler D, Lack J, Cam M, Pontier A, Nguyen YTM, Maejima K, Sasaki-Oku A, Nakano K, Tanaka H, Vander Griend D, Kubo M, Ratain MJ, Miyano S, Nakagawa H.

Eur Urol Focus. 2018 Feb 1. pii: S2405-4569(18)30007-5. doi: 10.1016/j.euf.2018.01.006. [Epub ahead of print]

15.

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy.

Goetz MP, Sangkuhl K, Guchelaar HJ, Schwab M, Province M, Whirl-Carrillo M, Symmans WF, McLeod HL, Ratain MJ, Zembutsu H, Gaedigk A, van Schaik RH, Ingle JN, Caudle KE, Klein TE.

Clin Pharmacol Ther. 2018 May;103(5):770-777. doi: 10.1002/cpt.1007. Epub 2018 Jan 31.

PMID:
29385237
16.

Intraindividual Pharmacokinetic Variability: Focus on Small-Molecule Kinase Inhibitors.

Chatelut E, Bruno R, Ratain MJ.

Clin Pharmacol Ther. 2018 Jun;103(6):956-958. doi: 10.1002/cpt.937. Epub 2017 Dec 1.

PMID:
29194586
17.

Metabolism of megestrol acetate in vitro and the role of oxidative metabolites.

House L, Seminerio MJ, Mirkov S, Ramirez J, Skor M, Sachleben JR, Isikbay M, Singhal H, Greene GL, Vander Griend D, Conzen SD, Ratain MJ.

Xenobiotica. 2018 Oct;48(10):973-983. doi: 10.1080/00498254.2017.1386335. Epub 2017 Nov 10.

PMID:
29050522
18.

Simplifying the use of pharmacogenomics in clinical practice: Building the genomic prescribing system.

Danahey K, Borden BA, Furner B, Yukman P, Hussain S, Saner D, Volchenboum SL, Ratain MJ, O'Donnell PH.

J Biomed Inform. 2017 Nov;75:110-121. doi: 10.1016/j.jbi.2017.09.012. Epub 2017 Sep 28.

PMID:
28963061
19.

Kinetic-Pharmacodynamic Model of Chemotherapy-Induced Peripheral Neuropathy in Patients with Metastatic Breast Cancer Treated with Paclitaxel, Nab-Paclitaxel, or Ixabepilone: CALGB 40502 (Alliance).

Mehrotra S, Sharma MR, Gray E, Wu K, Barry WT, Hudis C, Winer EP, Lyss AP, Toppmeyer DL, Moreno-Aspitia A, Lad TE, Valasco M, Overmoyer B, Rugo H, Ratain MJ, Gobburu JV.

AAPS J. 2017 Sep;19(5):1411-1423. doi: 10.1208/s12248-017-0101-9. Epub 2017 Jun 15.

20.

Pharmacogenomics-Based Point-of-Care Clinical Decision Support Significantly Alters Drug Prescribing.

O'Donnell PH, Wadhwa N, Danahey K, Borden BA, Lee SM, Hall JP, Klammer C, Hussain S, Siegler M, Sorrentino MJ, Davis AM, Sacro YA, Nanda R, Polonsky TS, Koyner JL, Burnet DL, Lipstreuer K, Rubin DT, Mulcahy C, Strek ME, Harper W, Cifu AS, Polite B, Patrick-Miller L, Yeo KT, Leung E, Volchenboum SL, Altman RB, Olopade OI, Stadler WM, Meltzer DO, Ratain MJ.

Clin Pharmacol Ther. 2017 Nov;102(5):859-869. doi: 10.1002/cpt.709. Epub 2017 Jun 15.

PMID:
28398598

Supplemental Content

Loading ...
Support Center